Skip to main content
At the 2023 ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder. 
Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.
Dr. Jack Cush reviews selected AOSD & systemic JIA abstracts from the ACR 2023 Annual meeting held in San Diego, November 12th thru 16th. Abstract 0761. EULAR / PreS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult Onset Still’s Disease (AOSD). Fautrel et a. 
Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of 13 European

Dr. John Cush RheumNow

2 years 8 months ago
Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease. https://t.co/UAlpww3fmi https://t.co/NpkTgwDuRl
Best of 2023: New Laboratory Insights for the ANA+ Consult

A new study suggests that use of ELISA assays for CXCL-10 a

Dr. John Cush RheumNow

2 years 8 months ago
Best of 2023: New Laboratory Insights for the ANA+ Consult A new study suggests that use of ELISA assays for CXCL-10 and IFN-α can predict which ANA+ individuals may progress to developing a systemic autoimmune rheumatic disease (SARD) https://t.co/5RgA143wLb https://t.co/JZU7ZX3Gty
AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It i

Dr. John Cush RheumNow

2 years 8 months ago

AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/Hw9RECWYg5 https://t.co/A5JMCSpl0D

The American College of Rheumatology released summaries of two new guidelines for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Disease and for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.
Rheumatoid arthritis related interstitial lung disease (RA-ILD) is common, with symptomatic RA-ILD affecting approximately 8% of RA patients. There is a very limited evidence base supporting treatment and therefore the recent release of ACR guidelines is to be welcomed. However, the published guidelines appear discordant with the best available evidence base. 
Time to Risk Stratify Methotrexate Lab Monitoring? A longitudinal cohort analysis has developed a prognostic model that

Dr. John Cush RheumNow

2 years 8 months ago
Time to Risk Stratify Methotrexate Lab Monitoring? A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy. https://t.co/R2TOzSO6cx https://t.co/XY3XEkSCT6
RA and cancer risk in the biologic era

RA is known to be historically associated with site specific cancers, especiall

Dr. John Cush RheumNow

2 years 8 months ago
RA and cancer risk in the biologic era RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era. https://t.co/ZOWFKTg3l3 https://t.co/1VLWgxVb0W
Chronic Pain Management tools
1 Medication
2 Physical Therapy
3 Cognitive-Behavioral Therapy
4 Mindfulness Meditation
5

Dr. John Cush RheumNow

2 years 8 months ago
Chronic Pain Management tools 1 Medication 2 Physical Therapy 3 Cognitive-Behavioral Therapy 4 Mindfulness Meditation 5 Acupuncture 6 Massage 7 Heat/Cold 8 TENS 9 Yoga/Tai Chi 10 Support groups https://t.co/VBvYR8VK16
FDA Approves Colchicine for CV Prevention. The FDA has approved colchicine for cardiovascular prevention in adults with

Dr. John Cush RheumNow

2 years 8 months ago
FDA Approves Colchicine for CV Prevention. The FDA has approved colchicine for cardiovascular prevention in adults with established atherosclerotic disease or multiple risk factors, making it the first anti-inflammatory medicine with such an indication. https://t.co/g6j9yvl1n2 https://t.co/RUip1o4MYZ
Best of 2023: 2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease

The prevalence of radiographic chon

Dr. John Cush RheumNow

2 years 8 months ago
Best of 2023: 2023 ACR/EULAR Criteria for Calcium Pyrophosphate Deposition Disease The prevalence of radiographic chondrocalcinosis is estimated to be 4% to ≥10% in older adults, but the prevalence of symptomatic CPPD disease is unknown. https://t.co/gsCtfHzn4Z https://t.co/lIaf36epZY
×